<DOC>
	<DOCNO>NCT01150617</DOCNO>
	<brief_summary>Primary objective study test whether intensified insulin therapy incorporate target normal fast glucose ( &lt; 5.5 mmol/L ) glycated hemoglobin &lt; 6.5 % able halve incidence angiographic restenosis 6 month ( expect rate 45 % , reduce 15 % ) peripheral angioplasty compare standard care achieve glycated hemoglobin &lt; 7.0 % patient type 2 diabetes limb ischemia . Secondary objective include identification marker associate , predictive , restenosis investigation underlie pathophysiological background , specific focus role nitric oxide ( NO ) , mechanisms endothelial activation/apoptosis , inflammation matrix remodel risk profile , candidate gene polymorphisms endothelial progenitor cell evaluation . Methodology : This randomize , open-label , clinical trial compare two regimen insulin therapy outcome measure incidence angiographic restenosis 6 month peripheral angioplasty . Seventy consecutive patient type 2 diabetes peripheral arterial disease undergoing peripheral angiography subsequent angioplastic procedure study . Patients treat intensive insulin therapy , base three pre-prandial administration regular insulin short act insulin analogue combine long-acting insulin analogue glargine standard care base once-daily insulin oral antidiabetic agent . Patients randomize intensive insulin therapy arm educate follow daily measurement fast glucose weekly phone contact target fast glucose &lt; 5.5 mmol/L ( 99 mg/dl ) obtain glycated hemoglobin &lt; 6.5 % . The control arm follow achieve target glycated hemoglobin &lt; 7.0 % . Life style recommendation , include diet physical activity program , two arm . All patient undergo three visit physical examination blood sampling , baseline 2 , 4 6 month angioplasty . Moreover , patient normal fast glucose arm monitor phone weekly basis order test adherence therapeutic target .</brief_summary>
	<brief_title>Normalization Fasting Glucose Incidence Restenosis After Peripheral Angioplasty</brief_title>
	<detailed_description>The principal objective project : Objectives Primary Objectives To determine role fast normoglycemia achieve long term ( 6 month ) intensify insulin therapy : - Reduction angiographic restenosis ( &gt; or=50 % ) peripheral angioplasty - Increase rate primary clinical success follow-up define continued relief ischemic rest pain , reduction severity claudication persistent hemodynamic success and/or symptomatic improvement least one category accord Rutherford criterion , heal ulceration , freedom unplanned surgical amputation bypass surgery - Definition beneficial effect normoglycemia insulin mediate nitric oxide ( NO ) modulation neointima formation action inflammation and/or matrix remodelling Secondary Objectives - To determine whether fast normoglycemia achieve intensified insulin therapy able reduce avoid plan unplanned major amputation limb loss metatarsal level minor amputation , transmetatarsal amputation removal distal part low extremity and/or performance less extensive amputation initially intend 6 month - To evaluate reduction Major Adverse Cardiovascular Event ( MACE ) define occurrence death , repeat target vessel revascularization - To find new risk profile systematically detectable index able define patient high risk develop restenosis - To correlate angiographic clinical index restenosis endothelial activation/apoptosis , inflammation matrix remodelling risk profile - To define association candidate gene variant degree restenosis - To understand impact fast normoglycemia achieve intensified insulin therapy endothelial progenitor cell isolation gene expression involve process vascular repair inhibition neointimal hyperplasia This randomize , open-label , clinical trial compare two regimen insulin therapy ( intensified insulin therapy v standard care ) determine fast normoglycemia achieve intensified insulin therapy able reduce incidence angiographic restenosis 6 month peripheral angioplasty . Seventy consecutive patient type 2 diabetes mellitus peripheral arterial disease ( PAD ) define angiographic evaluation and/or clinical manifestation , admit Institute undergo PTA procedure . After procedure , suitable patient screen enter study . One week follow hospital discharge PTA procedure , patient return Diabetology Outpatients Clinic randomly assign receive intensified insulin therapy standard care . Prestudy treatment could diet alone , oral antidiabetic agent , once-daily insulin oral antidiabetic agent . Two group evaluate - Intensified insulin therapy : three administration regular insulin short act insulin analogue meal combine long-acting insulin analogue glargine evening . The treatment goal fast blood glucose level 5.5 mmol/L ( 99 mg/dl ) HbA1c &lt; 6.5 % end follow-up . - Standard care : treatment once-daily long-acting insulin oral antidiabetic agent achieve HbA1c level &lt; 7.0 % end follow-up . Routine visit schedule 1 , 2 , 4 week 2 , 4 6 month . All patient ask monitor blood glucose level morning document hypoglycemia 1-day six point glucose profile ( 2 h breakfast , lunch dinner ) clinic visit . In intensified insulin therapy arm , patient contact telephone every week target fast glucose level 5.5 mmol/L titrate regimen . The following titration regimen follow , accord ( 48 ) : Mean self-monitored FPG value Increase long-acting insulin dosage ( UI ) &gt; 180 mg/dl ( &gt; 10 mmol/l ) 8 140-180 mg/dl ( 7.8-10 mmol/l ) 6 120-140 mg/dl ( 6.7-7.8 mmol/l ) 4 100-120 mg/dl ( 5.6-6.7 mmol/l ) 2 72-100 mg/dl ( 4.0-5.6 mmol/l ) change &lt; 72 mg/dl ( &lt; 4.0 mmol/l ) decrease 2 Ethics Approval The protocol accordance guideline contain `` Declaration Helsinki 2 '' current national legislation . The protocol , site 's informed consent form write information provide patient prior enrollment approve local Ethics Committee principal investigator take responsibility ensure procedure follow . If , study , necessary amend inform consent form , investigator responsible ensure local Ethics Committees review approves amend document enter new subject study . Discomforts patient include study case mild temporary . Risks involve participate study limit . Considering potential benefit relate prevent restenosis peripheral angioplasty diabetic patient , believe investigation justify . Utilization drug project subject Institutional National Safety Regulations ensure safety worker prevent damage environment community . Experimental design During hospitalization period , procedure , patient suitable enter study , blood sample draw breakfast evaluation plasma glucose , serum insulin plasma FFA . Samples drawn evaluate gene polymorphism , circulate endothelial progenitor cell isolation study insulin-mediated nitric oxide signal pathway . At time angiographic angioplastic procedure , blood sample draw femoral arterial venous district evaluation index endothelial activation/apoptosis , inflammation matrix remodelling . A venous sample take endothelial progenitor cell isolation gene expression evaluation . After procedure peripheral angiography angioplasty , Outpatient Clinic , randomisation , patient perform baseline physical examination blood sample evaluate metabolic parameter define degree glucose control indices endothelial activation/apoptosis , inflammation matrix remodelling DNA isolation . At time visit , patient randomly assign intensive insulin treatment 6 month standard care glycemic control , add usual cardiovascular treatment . A similar diet physical activity program plan group . At 2 , 4 6 month , physical examination blood sample evaluate metabolic parameter define degree glucose control indices endothelial activation/apoptosis , inflammation matrix remodelling repeat . Samples draw evaluate circulate endothelial progenitor cell study insulin-mediated nitric oxide signal pathway modulation prolong strict fasting normoglycemia . After 6 month presence symptom , perform angiographic control evaluate presence restenosis . At time , blood sample draw femoral arterial venous district evaluation index endothelial activation/apoptosis , inflammation matrix remodelling . A venous sample take endothelial progenitor cell isolation gene expression evaluation . During hospitalization period , blood sample draw breakfast evaluation plasma glucose , serum insulin plasma FFA .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Short-Acting</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>1 . Both gender 2 . Age 30 75 year 3 . Early type 2 diabetes , define FPG &gt; 7.0 mmol/l PPG 11.1 mmol/l great previous diagnosis diabetes 4 . Treatments accept Diet without pharmacological treatment One oral antidiabetic drug ( OAD : sulfonylurea , biguanides , meglitinides ) halfmaximum dose great Once daily insulin OAD 5 . Angiographic documentation infrapopliteal arterial disease ( stenosis &gt; 70 % occlusion ) 6 . Critical limb ischemia ( CLI ) define Persistent , recur rest pain require analgesia ankle systolic pressure &lt; 50 mm Hg and/or toe systolic pressure &lt; 30 mm Hg TcPO2 &lt; 30 mm Hg Ulceration , gangrene , nonhealing wound foot ankle systolic pressure &lt; 50 mm Hg toe systolic pressure &lt; 30 mm Hg TcPO2 &lt; 30 mm Hg Fontaine stag IIIIV rutherford category IVVI Lifestylelimiting claudication define Rutherford category II III associate jeopardized single vessel runoff complete trifurcation vessel occlusion . 7 . Subject able provide sign dated write informed consent 1 . Type 1 diabetes , define positivity GAD antibody measure radiobinding assay 2 . Unwilling inject insulin perform correct self monitor blood glucose 3 . Acute limb ischemia 4 . Buerger disease 5 . Severe contrast allergy 6 . Hypersensitivity aspirin and/or clopidogrel 7 . Systemic coagulopathy contraindicate antiaggregation therapy 8 . Hypercoagulation disorder 9 . Serum creatinine &gt; 2.0 mg/dl screen 10 . Active liver disease , ALT AST &gt; 2.5 time upper limit normal screen 11 . Chronic recurrent treatment systemic corticosteroid 12 . Malignant diseases 13 . Psychiatric disease make participation impossible 14 . Alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Normoglycemia</keyword>
	<keyword>Peripheral angioplasty</keyword>
</DOC>